PDCD1 and non-small cell lung carcinoma: Although the sample size of patients on anti-PD-L1 was small (13 and 9 patients in the discovery and validation sets, respectively), the combination anti-PD-L1 regimen showed a higher MPR than the combination anti-PD-1 as a neoadjuvant treatment for patients with NSCLC.